## Valeo Pharma's Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19

written by InvestorNews | February 23, 2021
In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of <u>Valeo Pharma Inc.</u> (CSE: VPH | OTCQB: VPHIF) about Valeo's recent <u>news release</u> on the use of its Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Steve went on to say "Hesperidin is a natural product with very good safety profile and potential efficacy." The Montreal Heart Institute is a leading institute that has done a number of trials. Steve commented that for them to be interested in Hesperidin is testament to the many hours of research "...demonstrating that Hesperidin could have a very positive effect on patients that are symptomatic with COVID-19."

Steve also provided an update on the commercial launch of Redesca™ which is a biosimilar used as a blood thinner. He said that the drug has "great market potential" and has recently received a <u>positive recommendation</u> for public reimbursement in Quebec. The company expects to launch the product in early May. "Our revenues are slated to almost triple in the current fiscal vear which ends October 21<sup>st</sup>," Steve commented.

To watch the full interview, <u>click here</u>

**About Valeo Pharma** 

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., <a href="click here">click here</a>

**Disclaimer:** Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.